Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2025International Journal of Innovative Technologies in Social ScienceOpen Access

Advances in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis - A Literature Review

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPaulina RedelADAleksandra Dzwonkowska

Discussion

Loading...

Member takes

Overview

Literature review shows diagnostic improvements and treatment options for idiopathic pulmonary fibrosis, suggesting better patient outcomes.

Key Points

  • Idiopathic pulmonary fibrosis is a severe chronic lung disease with an average survival of 3-5 years post-diagnosis.
  • Current treatments like pirfenidone and nintedanib can slow disease progression but do not reverse fibrosis.
  • Research is focusing on new drug targets like TGF-β and personalized therapy to improve treatment.
  • Lung transplantation remains the only definitive treatment for eligible patients with idiopathic pulmonary fibrosis.

Cite This Study

Redel et al. (2025) studied this question.

synapsesocial.com/papers/689a093fe6551bb0af8ced06https://doi.org/10.31435/ijitss.3(47).2025.3503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Regenerative Therapies in the Treatment of Idiopathic Pulmonary Fibrosis: A Literature Review2025
  2. 2Idiopathic Pulmonary Fibrosis: Current Pathogenetic Insights and Emerging Therapeutic Strategies2025
  3. 3Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?2025
  4. 4A Comprehensive Review on Pulmonary Fibrosis (PF): Histological Spectrum, Diagnosis, Risk Factors, Pathogenesis, Molecular Pathophysiology, and Current Treatment Options2025
  5. 5Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations2025